Navigation Links
Karolinska Development Invests in EvoStem Finland Oy

STOCKHOLM, January 12 /PRNewswire/ -- Sweden The Swedish investment company Karolinska Development AB has made a significant investment in EvoStem Finland Oy that develops stem cell and other tissue engineering based treatments for veterinary and human use.

In 2007 EvoStem Finland Oy introduced its first product TendoStem(R), which is a stem cell based treatment service for tendon and ligament injuries in horses. TendoStem(R) is currently on the market in Scandinavia.

"With this investment, we will speed up our international growth and product development projects," says Dr. Minna Leppanen, the CEO of EvoStem Finland Oy.

"We are targeting global markets, and currently we are engaged in negotiations for expansion of our market area. The investment of Karolinska Development AB and its strong, long-time commitment gives us a solid ground for a long-term development of our company," Leppanen continues.

"EvoStem has demonstrated that stem cell therapy for regenerative medicine is ready for the market. With our investment in EvoStem we strengthen our presence in the cell therapy area where we expect strong growth and medical progress," comments Investment Manager Hans-Peter Ekre, Karolinska Development AB.

About EvoStem Finland Oy

EvoStem Finland Oy develops, produces and markets stem cell based treatment methods for animals and man. The company's current focus is on orthopaedic and sports medicine applications. EvoStem Finland Oy was founded in 2005 as a spin-off of Tampere University Institute of Regenerative Medicine Regea and is based in Tampere, Finland.

About Karolinska Development

Managing one of the largest portfolios of life science research companies in Europe, Karolinska Development is a Swedish investment company using a unique, highly cost effective model to commercialize internationally renowned life science innovations. Professionals in business development and management, supported by a network of experienced technical specialists, ensure fast and efficient development. This enables Karolinska Development to rapidly build value in high risk opportunities, through long term lead investor position from seed stage; developing the medical products of the future. Karolinska Development's office is located at the Karolinska Institutet Science Park, Solna/Stockholm Sweden.

    For more information, please contact:
    CEO Minna Leppanen, EvoStem Finland Oy,
    mobile +358-40-504-4423,

    Investment Manager Hans-Peter Ekre, Karolinska Development AB,
    mobile +46-70-533-67-47,

SOURCE Karolinska Development and EvoStem
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Dr. Henry Barnett becomes first person outside Europe to receive Karolinska Stroke Award
2. The Feinstein to collaborate with Swedens Karolinska Institute
3. 3 new honorary doctors at Karolinska Institutet
4. Karolinska Institutets Pedersen to receive GSAs 2007 Distinguished Career Award
5. Reduce Risk, Achieve Compliance and Accelerate Time to Market with hiQual and Hiemstra Product Development
6. Blog Launched to Discuss Developments in Hydrophilic Coatings for Medical Devices
7. New Markets Development Program Brings Renovations, Equipment to Bastrop, Louisiana Hospital
8. New drug development still takes 8 years despite faster FDA review, according to Tufts CSDD
9. The Leukemia & Lymphoma Society and The University of Kansas Cancer Center Announce Innovative Partnership to Accelerate Drug Development
10. BioMarin and La Jolla Pharmaceutical Sign Worldwide (Excluding Asia Pacific) Development and Commercialization Agreement for Riquent
11. New Zealand Waynes New Resources Development Co., Ltd. Completes Reverse Merger to Go Public in the U.S.
Post Your Comments:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, ... the latter, setting the bar too high can result in disappointment, perhaps even self-loathing. ... toward their goal. , Research from reveals that behind the ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle ... chronic pain and the benefits of holistic treatments, Serenity Recovery Center of ... Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
(Date:6/23/2016)... a startling report released today, National Safety Council research ... proven plan to eliminate prescription opioid overdoses. Prescription Nation ... tackling the worst drug crisis in recorded U.S. history, assigned a ... , New Mexico , Tennessee ... failing states, three – Michigan , ...
(Date:6/23/2016)... 23, 2016 Bracket , a leading clinical ... generation clinical outcomes platform, Bracket eCOA (SM) 6.0, at ... 26 – 30, 2016 in Philadelphia , ... Outcome Assessment product of its kind to fully integrate with ... Bracket eCOA 6.0 is a flexible platform for electronic clinical ...
Breaking Medicine Technology: